Creatine and cyclocreatine attenuate MPTP neurotoxicity.
about
The promise of neuroprotective agents in Parkinson's diseaseBrain serotonin and dopamine modulators, perceptual responses and endurance performance during exercise in the heat following creatine supplementationCreatine for Parkinson's diseaseCreatine for Parkinson's diseaseThe role of oxidative stress in Parkinson's diseaseCreatine metabolism and psychiatric disorders: Does creatine supplementation have therapeutic value?Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent PerspectivesNutraceuticals in Parkinson's DiseaseA review on mitochondrial restorative mechanism of antioxidants in Alzheimer's disease and other neurological conditionsElectron Transport Disturbances and Neurodegeneration: From Albert Szent-Györgyi's Concept (Szeged) till Novel Approaches to Boost Mitochondrial BioenergeticsOxidative Stress in Neurodegenerative DiseasesAnti-Oxidants in Parkinson's Disease Therapy: A Critical Point of ViewPhosphocreatine interacts with phospholipids, affects membrane properties and exerts membrane-protective effectsExpression of creatine kinase isoenzyme genes during postnatal development of rat brain cerebellum: evidence for transcriptional regulationC. elegans S6K Mutants Require a Creatine-Kinase-like Effector for Lifespan ExtensionComparative expression analysis of the phosphocreatine circuit in extant primates: Implications for human brain evolutionMitochondrial therapy for Parkinson's disease: neuroprotective pharmaconutrition may be disease-modifyingA pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month resultsEffect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1.Creatine kinase B-driven energy transfer in the brain is important for habituation and spatial learning behaviour, mossy fibre field size and determination of seizure susceptibility.On the mechanisms of neuroprotection by creatine and phosphocreatine.Enhancement of L-3-hydroxybutyryl-CoA dehydrogenase activity and circulating ketone body levels by pantethine. Relevance to dopaminergic injury.Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.A potential role for creatine in drug abuse?Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases.Irreversible brain creatine deficiency with elevated serum and urine creatine: a creatine transporter defect?Therapeutic use of creatine in brain or heart ischemia: available data and future perspectives.Targeting cellular energy production in neurological disorders.Mitochondrial dysfunction in Parkinson's disease: pathogenesis and neuroprotection.Animal models of Parkinson's disease.Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior.Antioxidants as treatment for neurodegenerative disorders.A review of creatine supplementation in age-related diseases: more than a supplement for athletes.Mitochondrial enhancement for neurodegenerative movement disorders: a systematic review of trials involving creatine, coenzyme Q10, idebenone and mitoquinone.Reactive oxygen species in skeletal muscle signaling.The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease.Synchrotron radiation Fourier-transform infrared and Raman microspectroscopy study showing an increased frequency of creatine inclusions in the rat hippocampal formation following pilocarpine-induced seizuresD-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease.Physiological phenotype and vulnerability in Parkinson's disease
P2860
Q21129436-1713DA3A-7069-4AFA-A3B5-4DB2325C8540Q21245420-F688D5F9-0298-416F-A397-8BF75CBE37F3Q24193947-A599087B-7A0C-4343-98C1-DD96BBDD5E1CQ24203799-240D1BFA-F81C-46F6-9F0C-7BED4BCA9F04Q24307946-18D66F72-FA5D-442C-B64C-32C4FD9E5CD9Q24631151-E3DC8DA6-64FF-436E-A8E4-105DBE2805E9Q26747508-93BF9BF0-EC58-42CC-AC20-48E860EF5AB2Q26752769-4D8EBBD3-7560-453E-B357-6F7B58A86EA7Q26781560-208A32C7-3ECF-421D-A888-70588D4DC967Q26795417-A63E34BB-4691-40E5-97B7-636DE6EE5596Q26801239-15A38623-4E08-4B59-B745-AC5CAB017C67Q28084254-0587A62B-79F9-40F0-A67F-9064B66E3245Q28482353-D62DC8AD-1F91-4A40-8F6D-B87CA228C2D3Q28579012-6E6E05F7-4420-4401-A2E0-931C0900748CQ28601083-E128A171-46F3-465C-8170-91DDE06AF0D1Q28654485-298B7485-0F0E-4874-B0D3-EA954BC162F3Q28732683-E2572222-46E8-4333-BF9B-66B7FB50A772Q30407150-621591A5-CE5F-4784-92A0-8D6009AC2EBFQ30407589-A08CCAA6-EF27-404C-8DE3-52251E10482EQ30417007-78844DF7-508E-4FEE-988A-7B030B822FFBQ30697610-261C3BB4-C404-4753-9E13-4427063A053FQ32034781-4E6FD2BC-2233-40C3-ABBD-EF1D050B7279Q33563284-6FA77B77-6614-42A4-AF91-74651BA201EFQ33837238-EFCAD6D7-6E65-4FC5-8F2B-68B196066E3BQ33844763-C2D78395-6D20-4AEC-9E5B-5C08E1D60582Q33917550-157173FD-73E2-45B9-ACA3-316D22427691Q33939183-8D924BD8-8873-48A6-8605-31C71302E953Q34089086-DD94911F-393E-42D0-9151-5D62B42D1CCAQ34266266-065120F6-C2BE-4887-9ED1-38FF4B68228CQ34460675-1599A230-C656-475A-8A34-0CC2ED468227Q34596189-FA68906F-B443-457A-B9E8-AA0EBB370131Q34711201-9CCF33FA-9C1D-4454-9C93-C029533053D2Q34974866-DCD0D0E2-07AA-4D64-83A1-D24CE04CFAABQ35005568-EA6A5363-1229-49DF-9FDA-38A30B1EBA00Q35045060-CC490387-251B-40D8-8009-D1353E5E4DE1Q35607438-EB02DB07-1743-402F-A499-ECC0C704B28CQ35628604-76269EA0-0A39-48BC-A41F-16E3C01DB0BBQ35761665-AD45B0ED-9366-4426-9E63-0DA85CF26C19Q35919815-CDFF9E33-8FF9-4EB9-AEAE-5F144B7583E1Q36065850-C87BE0D6-D002-41CA-86D9-804DD9A4623C
P2860
Creatine and cyclocreatine attenuate MPTP neurotoxicity.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Creatine and cyclocreatine attenuate MPTP neurotoxicity.
@en
Creatine and cyclocreatine attenuate MPTP neurotoxicity.
@nl
type
label
Creatine and cyclocreatine attenuate MPTP neurotoxicity.
@en
Creatine and cyclocreatine attenuate MPTP neurotoxicity.
@nl
prefLabel
Creatine and cyclocreatine attenuate MPTP neurotoxicity.
@en
Creatine and cyclocreatine attenuate MPTP neurotoxicity.
@nl
P2093
P356
P1476
Creatine and cyclocreatine attenuate MPTP neurotoxicity.
@en
P2093
Ferrante RJ
Kaddurah-Daouk R
Klivenyi P
Matthews RT
P304
P356
10.1006/EXNR.1999.7049
P407
P577
1999-05-01T00:00:00Z